This site is intended for Healthcare professionals only.
Elsevier-Clinicalkey

Takeda gets European panel nod for Alunbrig to treat lung cancer


Takeda gets European panel nod for Alunbrig to treat lung cancer
The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended granting Japan-based Takeda’s Alunbrig, or brigatinib, a marketing authorisation.
New Delhi; Takeda Pharmaceutical Co’s lung cancer drug received the recommendation of a European Union panel on Friday, more than a year after it won regulatory approval to be sold in the United States.

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended granting Japan-based Takeda’s Alunbrig, or brigatinib, a marketing authorisation.

The panel’s recommendations are generally followed by European regulators.

Alunbrig was approved last year by the U.S. Food and Drug Administration as a second-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer, who have progressed on or are intolerant to Pfizer drug crizotinib, the standard initial treatment for the disease.

(Reporting by Sangameswaran S in Bengaluru; Editing by Sai Sachin Ravikumar)



Source: Reuters
0 comment(s) on Takeda gets European panel nod for Alunbrig to treat lung cancer

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted